Brodalumab in the Treatment of Various Forms of Psoriasis: A Narrative Review

• Published in: Journal of Dermatology and Dermatologic Surgery
• Main Authors: Aditya K. Bubna, Vinayak Viplav
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2025-01-01
• Subjects: brodalumab; plaque psoriasis; psoriatic arthritis
• Online Access: https://journals.lww.com/10.4103/jdds.jdds_41_24
• ISSN: 2352-2410; 2352-2429

Background: Brodalumab is a fully human monoclonal antibody that selectively targets the interleukin-17 receptor A (IL-17RA), blocking the activity of pro-inflammatory IL-17 cytokines. Purpose: The purpose of this study was to describe the efficacy and safety of brodalumab in treating various forms of psoriasis. Methods: PubMed, Google Scholar, Scopus, and ResearchGate were searched for scholarly articles related to brodalumab and its utility in psoriasis vulgaris, including all other variants of psoriasis using the search terms “brodalumab” AND “plaque psoriasis” AND “psoriasis variants” AND “psoriatic arthropathy.” Results: Brodalumab is rapidly and consistently effective for moderate-to-severe plaque psoriasis, with high rates of skin clearance. It is also effective for difficult-to-treat variants such as scalp, nail, genital, palmoplantar, erythrodermic, and pustular psoriasis, as well as psoriatic arthritis with an acceptable safety profile. Conclusion: The unique mechanism of brodalumab in blocking multiple IL-17 cytokines may contribute to its efficacy in patients who have failed other biological therapies. Adverse effects observed with brodalumab are generally mild; candidiasis and flares of inflammatory bowel disease are potential risks. Brodalumab is a valuable therapeutic option for psoriatic disease including psoriatic arthropathy.